Eli Lilly is dropping CVS Caremark as the administrator of drug benefits for its 50,000 employees next year, Bloomberg reported Nov. 12.
Lilly selected Rightway as its new PBM partner. The move comes after Caremark selected Novo Nordisk’s Wegovy over Lilly’s Zepbound as the preferred GLP-1 medication for its largest commercial formularies earlier this year.
The formulary change was a blow to Lilly, which began selling higher doses of Zepbound, a weight loss drug, for $499 at first fill in late February. In March, Novo Nordisk launched NovoCare Pharmacy to provide direct-to-patient doses of Wegovy for $499 per month.
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 2–3 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.